Interim report January – July 2010

2010-07-15 - 08:30

Good growth in sales and profitability with continuous concentration on strategic investments. 

Period January – June

 

  • Growth in local currency was 14 percent. Sales amounted to SEK 149 (142) million, corresponding to an increase of 5 percent in SEK.
  • Operating income before research and development costs increased by 14 percent and amounted to SEK 41 (36) million.
  • Operating income (EBIT) increased by 13 percent and amounted to SEK 19 (17) million. The operating margin was 13 (12) percent.
  • The Group’s net income amounted to SEK 19 (16) million.

 

 

 

Quarter in brief

 

  • Growth in local currency was 13 percent. Sales amounted to SEK 73 (70) million, corresponding to an increase of 4 percent in SEK.
  • Operating income before research and development costs increased by 7 percent and amounted to SEK 20 (19) million.
  • Operating income (EBIT) increased by 11 percent and amounted to SEK 9 (8) million. The operating margin was 12 (11) percent.
  • The Group’s net income amounted to SEK 9 (7) million, which gives earnings per share of SEK 0.48 (0.38).
  • The cash flow from operating activities was SEK 13 (12).
  • Dividend paid by 0.50 SEK per share.
  • The clinical study on STEEN Solution™ presented good treatment results.
  • Collaboration agreement with University of Melbourne regarding development of stem cell media.
  • Collaboration agreement with the Danish company HertART Aps regarding development of fertility products.  
  • Good clinical results from Swemed Sense™ multicenter study presented.

 

 

July 15, 2010

Gothenburg

 

Magnus Nilsson

CEO

 

 

Queries should be addressed to:

Magnus Nilsson, CEO; phone +46 31 721 80 61

Eva Nilsagård, CFO, phone +46 31 721 80 13